http://purl.org/np/RA-OpC-1Qans7Mk9f3nzHpcOZGwXOyq6zHTfHsd72OzGw#Head
http://purl.org/np/RA-OpC-1Qans7Mk9f3nzHpcOZGwXOyq6zHTfHsd72OzGw
http://www.nanopub.org/nschema#hasAssertion
http://purl.org/np/RA-OpC-1Qans7Mk9f3nzHpcOZGwXOyq6zHTfHsd72OzGw#assertion
http://purl.org/np/RA-OpC-1Qans7Mk9f3nzHpcOZGwXOyq6zHTfHsd72OzGw
http://www.nanopub.org/nschema#hasProvenance
http://purl.org/np/RA-OpC-1Qans7Mk9f3nzHpcOZGwXOyq6zHTfHsd72OzGw#provenance
http://purl.org/np/RA-OpC-1Qans7Mk9f3nzHpcOZGwXOyq6zHTfHsd72OzGw
http://www.nanopub.org/nschema#hasPublicationInfo
http://purl.org/np/RA-OpC-1Qans7Mk9f3nzHpcOZGwXOyq6zHTfHsd72OzGw#pubInfo
http://purl.org/np/RA-OpC-1Qans7Mk9f3nzHpcOZGwXOyq6zHTfHsd72OzGw
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.nanopub.org/nschema#Nanopublication
http://purl.org/np/RA-OpC-1Qans7Mk9f3nzHpcOZGwXOyq6zHTfHsd72OzGw#assertion
http://purl.obolibrary.org/obo/MONDO_0004985
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
https://w3id.org/biolink/vocab/Disease
http://purl.org/np/RA-OpC-1Qans7Mk9f3nzHpcOZGwXOyq6zHTfHsd72OzGw#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#object
http://purl.obolibrary.org/obo/MONDO_0004985
http://purl.org/np/RA-OpC-1Qans7Mk9f3nzHpcOZGwXOyq6zHTfHsd72OzGw#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate
https://w3id.org/biolink/vocab/treats
http://purl.org/np/RA-OpC-1Qans7Mk9f3nzHpcOZGwXOyq6zHTfHsd72OzGw#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#subject
https://identifiers.org/DRUGBANK:DB01224
http://purl.org/np/RA-OpC-1Qans7Mk9f3nzHpcOZGwXOyq6zHTfHsd72OzGw#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement
http://purl.org/np/RA-OpC-1Qans7Mk9f3nzHpcOZGwXOyq6zHTfHsd72OzGw#association
http://www.w3.org/2000/01/rdf-schema#label
When we asked about the long-term treatment of BD, after having excluded from the analyses the 3 SGAs with a European indication for maintenance BD treatment (aripiprazole, olanzapine, and quetiapine), asenapine was considered either “highly appropriate” or “appropriate” by 44.6% of the respondents, while other off-label SGAs (clozapine, paliperidone, risperidone, ziprasidone) were mostly considered inappro- priate for maintenance bipolar treatment
http://purl.org/np/RA-OpC-1Qans7Mk9f3nzHpcOZGwXOyq6zHTfHsd72OzGw#association
https://w3id.org/biolink/vocab/has_population_context
http://purl.org/np/RA-OpC-1Qans7Mk9f3nzHpcOZGwXOyq6zHTfHsd72OzGw#context
http://purl.org/np/RA-OpC-1Qans7Mk9f3nzHpcOZGwXOyq6zHTfHsd72OzGw#association
https://w3id.org/biolink/vocab/provided_by
https://w3id.org/um/NeuroDKG
http://purl.org/np/RA-OpC-1Qans7Mk9f3nzHpcOZGwXOyq6zHTfHsd72OzGw#association
https://w3id.org/biolink/vocab/publications
https://pubmed.ncbi.nlm.nih.gov/31291215
http://purl.org/np/RA-OpC-1Qans7Mk9f3nzHpcOZGwXOyq6zHTfHsd72OzGw#association
https://w3id.org/biolink/vocab/relation
https://w3id.org/um/neurodkg/OffLabelIndication
http://purl.org/np/RA-OpC-1Qans7Mk9f3nzHpcOZGwXOyq6zHTfHsd72OzGw#context
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
https://w3id.org/biolink/vocab/Cohort
http://purl.org/np/RA-OpC-1Qans7Mk9f3nzHpcOZGwXOyq6zHTfHsd72OzGw#context
http://www.w3.org/2000/01/rdf-schema#label
Adults
https://identifiers.org/DRUGBANK:DB01224
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
https://w3id.org/biolink/vocab/Drug
http://purl.org/np/RA-OpC-1Qans7Mk9f3nzHpcOZGwXOyq6zHTfHsd72OzGw#provenance
http://purl.org/np/RA-OpC-1Qans7Mk9f3nzHpcOZGwXOyq6zHTfHsd72OzGw#assertion
http://www.w3.org/ns/prov#generatedAtTime
2021-08-17T13:35:49.030571
http://purl.org/np/RA-OpC-1Qans7Mk9f3nzHpcOZGwXOyq6zHTfHsd72OzGw#pubInfo
http://purl.org/np/RA-OpC-1Qans7Mk9f3nzHpcOZGwXOyq6zHTfHsd72OzGw#sig
http://purl.org/nanopub/x/hasAlgorithm
RSA
http://purl.org/np/RA-OpC-1Qans7Mk9f3nzHpcOZGwXOyq6zHTfHsd72OzGw#sig
http://purl.org/nanopub/x/hasPublicKey
MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCamPJb4SzqpLXn//XJ5dlVfzz6QI+RPmiJTLXF/by2JR7sHMKRsCQDFsYMlq8zGHghOIkjRP9dpLZUtZzUcHt3MXiFKEPo8eGzUe9p+JXKFC8xxkJr94z2vq6IdMf71Iu1GH8SeDAKt/DgYO4zNaw8VuXvxnZRewKZSA+u8zWPVwIDAQAB
http://purl.org/np/RA-OpC-1Qans7Mk9f3nzHpcOZGwXOyq6zHTfHsd72OzGw#sig
http://purl.org/nanopub/x/hasSignature
IQK9u9OLH0mCXBYr1jkEIDsC+sVqHSbyr56NsNTc1W6j4V/nJSdRR1iI95x+x84IXmdYA4SWVac594zDWVl5us1ejyGQcreRTRSIQFca2LFJqPQQO8JvwJ0v9ffi/vfEqW2ZS8nXAZIiZQBUfh3FROO6EkkaMSs2ivayzOvx77I=
http://purl.org/np/RA-OpC-1Qans7Mk9f3nzHpcOZGwXOyq6zHTfHsd72OzGw#sig
http://purl.org/nanopub/x/hasSignatureTarget
http://purl.org/np/RA-OpC-1Qans7Mk9f3nzHpcOZGwXOyq6zHTfHsd72OzGw
http://purl.org/np/RA-OpC-1Qans7Mk9f3nzHpcOZGwXOyq6zHTfHsd72OzGw
http://www.w3.org/ns/prov#generatedAtTime
2021-08-17T13:35:49.030571
http://purl.org/np/RA-OpC-1Qans7Mk9f3nzHpcOZGwXOyq6zHTfHsd72OzGw
http://www.w3.org/ns/prov#wasAttributedTo
https://orcid.org/0000-0002-7641-6446
http://purl.org/np/RA-OpC-1Qans7Mk9f3nzHpcOZGwXOyq6zHTfHsd72OzGw
https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate
http://purl.org/np/RAhNHZw6Urw_Mccs4qy6Ws3C9CRuaHpQx8AwuApbWkqnY